Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00019-21.
Human immunodeficiency virus (HIV) persistence in tissue reservoirs is a major barrier to HIV cure. While antiretrovirals (ARVs) suppress viral replication, antiretroviral therapy (ART) interruption results in rapid rebound viremia that may originate from lymphoid tissues. To understand the relationship between anatomic distribution of ARV exposure and viral expression in lymph nodes, we performed mass spectrometry imaging (MSI) of 6 ARVs, RNAscope hybridization for viral RNA (vRNA), and immunohistochemistry of collagen in mesenteric lymph nodes from 8 uninfected and 10 reverse transcriptase simian/human immunodeficiency virus (RT-SHIV)-infected rhesus macaques dosed to steady state with combination ART. MATLAB-based quantitative imaging analysis was used to evaluate spatial and pharmacological relationships between these ARVs, viral RNA (both vRNA cells and follicular dendritic cell [FDC]-bound virions), and collagen deposition. Using MSI, 31% of mesenteric lymph node tissue area was found to be not covered by any ARV. Additionally, 28% of FDC-trapped virions and 21% of infected cells were not exposed to any detected ARV. Of the 69% of tissue area that was covered by cumulative ART exposure, nearly 100% of concentrations were greater than 50% inhibitory concentration (IC) values; however, 52% of total tissue coverage was from only one ARV, primarily maraviroc. Collagen covered ∼35% of tissue area but did not influence ARV distribution heterogeneity. Our findings are consistent with our hypothesis that ARV distribution, in addition to total-tissue drug concentration, must be considered when evaluating viral persistence in lymph nodes and other reservoir tissues.
人类免疫缺陷病毒 (HIV) 在组织储库中的持续存在是 HIV 治愈的主要障碍。虽然抗逆转录病毒药物 (ARV) 抑制病毒复制,但抗逆转录病毒治疗 (ART) 的中断会导致病毒迅速反弹,这可能起源于淋巴组织。为了了解 ARV 暴露的解剖分布与淋巴结中病毒表达之间的关系,我们对 6 种 ARV 进行了质谱成像 (MSI)、病毒 RNA (vRNA) 的 RNAscope 杂交以及肠系膜淋巴结中胶原的免疫组织化学分析,来自 8 只未感染和 10 只逆转录酶猴/人免疫缺陷病毒 (RT-SHIV) 感染的恒河猴,用联合 ART 进行了稳态剂量给药。使用基于 MATLAB 的定量成像分析来评估这些 ARV、病毒 RNA(vRNA 细胞和滤泡树突状细胞 [FDC] 结合的病毒)和胶原沉积之间的空间和药物关系。通过 MSI,发现肠系膜淋巴结组织面积的 31%未被任何 ARV 覆盖。此外,28%的 FDC 捕获的病毒和 21%的感染细胞未接触到任何检测到的 ARV。在被累积 ART 暴露覆盖的 69%的组织面积中,几乎 100%的浓度大于 50%抑制浓度 (IC) 值;然而,52%的总组织覆盖率仅来自一种 ARV,主要是马拉维若。胶原覆盖了约 35%的组织面积,但不影响 ARV 分布的异质性。我们的研究结果与我们的假设一致,即除了组织中的总药物浓度外,在评估淋巴结和其他储库组织中的病毒持续性时,还必须考虑 ARV 的分布。